HKPD
Cellyan Biotechnology·NASDAQ
--
--(--)
--
--(--)
HKPD fundamentals
During H1 2026, Cellyan Biotechnology (HKPD) reported revenue of 7.14M, a YoY change of -35.65%. Net income was 153.74K, a YoY change of -81.45%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | H1,2026 | TTM |
|---|
Start Date | Apr 1, 2022 | Apr 1, 2023 | Apr 1, 2023 | Apr 1, 2024 | Apr 1, 2024 | Apr 1, 2025 | -- |
End Date | Mar 31, 2023 | Sep 30, 2023 | Mar 31, 2024 | Sep 30, 2024 | Mar 31, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | -- |
Revenue | 12.56M -- | 7.01M -- | 16.69M +32.91% | 11.09M +58.24% | 20.31M +21.72% | 7.14M -35.65% | 16.36M -- |
Sales and Services Revenue | 12.53M -- | 7.01M -- | 16.36M +30.57% | 11.09M +58.24% | 19.99M +22.18% | 7.14M -35.65% | 16.04M -- |
Other Revenue | 23.04K -- | -- -- | 324.71K +1309.52% | -- -- | 321.04K -1.13% | -- -- | -- -- |
Cost of Revenue | 9.82M -- | 5.67M -- | 13.13M +33.74% | 9.19M +61.91% | 17.90M +36.32% | 6.21M -32.43% | 14.92M -- |
Cost of Goods and Services | 9.82M -- | 5.67M -- | 13.13M +33.74% | 9.19M +61.91% | 17.90M +36.32% | 6.21M -32.43% | 14.92M -- |
Gross Profit | 2.74M -- | 1.34M -- | 3.56M +29.93% | 1.91M +42.64% | 2.42M -32.13% | 930.76K -51.16% | 1.44M -- |
Other Operating Income | 96.23K -- | 427 -- | 4.04K -95.80% | 804 +88.29% | 1.47K -63.69% | 38.90K +4738.06% | 39.56K -- |
Operating Expenses | 1.76M -- | 994.78K -- | 1.90M +8.10% | 881.12K -11.43% | 2.23M +17.40% | 724.62K -17.76% | 2.08M -- |
Selling, General and Administrative Expenses | 1.76M -- | 994.78K -- | 1.89M +7.47% | 881.12K -11.43% | 2.22M +17.28% | 724.62K -17.76% | 2.06M -- |
Loss on Disposal of Assets | 0 -- | -- -- | 10.85K -- | -- -- | 7.53K -30.64% | -- -- | -- -- |
Other Operating Expenses | 2.04K -- | -- -- | 2.47K +21.02% | -- -- | 10.52K +325.75% | -- -- | -- -- |
Operating Income | 1.08M -- | 341.64K -- | 1.66M +54.41% | 1.03M +200.11% | 182.72K -88.99% | 245.04K -76.10% | -597.52K -- |
Non-Operating Income (Loss) | -54.26K -- | -67.47K -- | -133.96K -146.87% | -46.42K +31.19% | -146.61K -9.45% | -73.24K -57.77% | -173.43K -- |
Gain (Loss) on Other Investment | 0 -- | 11.56K -- | 11.56K -- | -- -- | -43.15K -473.26% | -- -- | -- -- |
Gain (Loss) on Foreign Currency Exchange | -31.24K -- | -31.23K -- | -63.23K -102.38% | 1.75K +105.61% | -7.54K +88.07% | -10.73K -712.56% | -20.02K -- |
Other Non-Operating Income (Loss) | -- -- | -13.14K -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | 23.02K -- | 34.66K -- | 82.29K +257.43% | 48.18K +39.01% | 95.93K +16.57% | 62.52K +29.77% | 110.27K -- |
Interest Expense | 23.24K -- | 34.81K -- | 82.77K +256.11% | 49.25K +41.49% | 97.67K +18.00% | 62.85K +27.60% | 111.26K -- |
Interest Income | 219 -- | 156 -- | 474 +116.44% | 1.08K +591.03% | 1.74K +267.30% | 330 -69.39% | 993 -- |
Pretax Income From Continuing Operations | 1.02M -- | 274.16K -- | 1.53M +49.49% | 978.86K +257.04% | 36.11K -97.63% | 171.80K -82.45% | -770.95K -- |
Income Tax Expense | 22.57K -- | 25.13K -- | 196.25K +769.37% | 150.30K +498.17% | 63.17K -67.81% | 18.07K -87.98% | -69.07K -- |
Current Income Tax | 22.57K -- | -- -- | 196.25K +769.37% | 150.30K -- | 63.17K -67.81% | 18.07K -87.98% | -69.07K -- |
Net Income | 998.20K -- | 249.04K -- | 1.33M +33.21% | 828.56K +232.71% | -27.06K -102.03% | 153.74K -81.45% | -701.88K -- |
Net Income Attributable to Minority Interests | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Owners of the Company | 998.20K -- | 249.04K -- | 1.33M +33.21% | 828.56K +232.71% | -27.06K -102.03% | 153.74K -81.45% | -701.88K -- |
Net Income Attributable to Common Stockholders | 998.20K -- | 249.04K -- | 1.33M +33.21% | 828.56K +232.71% | -27.06K -102.03% | 153.74K -81.45% | -701.88K -- |
Other Comprehensive Income | 640 -- | 227 -- | -516 -180.63% | 20.03K +8724.67% | 15.68K +3138.18% | -73 -100.36% | -4.43K -- |
Total Comprehensive Income | 998.84K -- | 249.26K -- | 1.33M +33.07% | 848.59K +240.44% | -11.38K -100.86% | 153.66K -81.89% | -706.31K -- |
Total Comprehensive Income Attributable to Owners of the Company | 998.84K -- | 249.26K -- | 1.33M +33.07% | 848.59K +240.44% | -11.38K -100.86% | 153.66K -81.89% | -706.31K -- |
Basic EPS | 0.15 -- | 0.04 -- | 0.18 +20.00% | 0.08 +100.00% | 0 -100.00% | 0.01 -87.50% | -0.07 -- |
Basic EPS from Continuing Operations | 0.15 -- | 0.04 -- | 0.18 +20.00% | 0.08 +100.00% | 0 -100.00% | 0.01 -87.50% | -0.07 -- |
Diluted EPS | 0.15 -- | 0.04 -- | 0.18 +20.00% | 0.08 +100.00% | 0 -100.00% | 0.01 -87.50% | -0.07 -- |
Diluted EPS from Continuing Operations | 0.15 -- | 0.04 -- | 0.18 +20.00% | 0.08 +100.00% | 0 -100.00% | 0.01 -87.50% | -0.07 -- |
You can ask Aime
What guidance did Cellyan Biotechnology's management provide for the next earnings period?What were the key takeaways from Cellyan Biotechnology’s earnings call?What factors drove the changes in Cellyan Biotechnology's revenue and profit?What is Cellyan Biotechnology's latest dividend and current dividend yield?What were the key takeaways from Cellyan Biotechnology's earnings call?What does Cellyan Biotechnology do and what are its main business segments?What is Cellyan Biotechnology's gross profit margin?Did Cellyan Biotechnology beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
